2023
Honoring the gift: The transformative potential of transplant-declined human organs
Albert C, Harris M, DiRito J, Shi A, Edwards C, Harkins L, Lysyy T, Kulkarni S, Mulligan D, Hosgood S, Watson C, Friend P, Nicholson M, Haakinson D, Saeb-Parsy K, Tietjen G. Honoring the gift: The transformative potential of transplant-declined human organs. American Journal Of Transplantation 2023, 23: 165-170. PMID: 36695696, DOI: 10.1016/j.ajt.2022.11.015.Peer-Reviewed Original Research
2021
Living Donor Nephrectomy: Approaches, Innovations, and Outcomes
Merola J, Cooper M, Kulkarni S. Living Donor Nephrectomy: Approaches, Innovations, and Outcomes. 2021, 291-302. DOI: 10.1007/978-3-030-53618-3_13.Peer-Reviewed Original ResearchDonor nephrectomySuperior long-term outcomesLong-term outcomesCareful preoperative planningSingle-port surgeryKidney transplantationSurgical riskDeceased donorsOrgan recipientsSurgical approachSurgical considerationsSurgical techniqueKidney donationNephrectomyPreoperative planningInformed consentOutcomesAdequate trainingRiskDonorsAllograftsDonationSurgeryTransplantationSurgeonsLeveling-up versus leveling-down to address health disparities in transplantation
Kulkarni S, Ladin K. Leveling-up versus leveling-down to address health disparities in transplantation. American Journal Of Transplantation 2021, 21: 917-918. PMID: 33326686, PMCID: PMC7986107, DOI: 10.1111/ajt.16458.Peer-Reviewed Original Research
2017
A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation
Kulkarni S, Do A, Liapakis A. A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation. Internal Medicine Review 2017, 3 DOI: 10.18103/imr.v3i9.570.Peer-Reviewed Original Research
2016
Parathyroidectomy prior to kidney transplant decreases graft failure
Callender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, Carling T, Tomlin R, Smith JD, Kulkarni S. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery 2016, 161: 44-50. PMID: 27863776, DOI: 10.1016/j.surg.2016.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesConfidence IntervalsDatabases, FactualFemaleGraft RejectionGraft SurvivalHumansHyperparathyroidismKidney Failure, ChronicKidney TransplantationMaleMiddle AgedOdds RatioParathyroid HormoneParathyroidectomyPreoperative CareRetrospective StudiesRisk AssessmentTreatment OutcomeConceptsYear post-kidney transplantationPost-kidney transplantationDelayed graft functionGraft failureKidney transplantationGraft functionParathyroid hormoneUremic hyperparathyroidismKidney diseaseFirst year post-kidney transplantationSerum parathyroid hormone levelsCurrent Kidney DiseaseGlobal Outcomes (KDIGO) guidelinesParathyroid hormone levelsSerum parathyroid hormoneAdult patientsKidney transplantOutcomes guidelinesRetrospective reviewSingle institutionCurrent guidelinesHormone levelsSurvival 1ParathyroidectomyTransplantation
2015
The Stanford Integrated Psychosocial Assessment for transplantation, healthcare utilization, and adverse medical events for 3years post-kidney transplantation
Zimbrean P, Patron-Lozano, Edgington N, Joyce M, Gaffney C, Skrip L, Wang J, Kulkarni S. The Stanford Integrated Psychosocial Assessment for transplantation, healthcare utilization, and adverse medical events for 3years post-kidney transplantation. Journal Of Psychosomatic Research 2015, 78: 634. DOI: 10.1016/j.jpsychores.2015.03.149.Peer-Reviewed Original Research
2014
The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation.
Thiessen C, PatronLozano R, Edgington N, Joyce M, Gaffney C, Skrip L, Wang J, Zimbrean P, Kulkarni S. The Stanford Integrated Psychosocial Assessment for Transplantation, Healthcare Utilization, and Adverse Medical Events for 3 Years Post-Kidney Transplantation. Transplantation 2014, 98: 576. DOI: 10.1097/00007890-201407151-01938.Peer-Reviewed Original ResearchEculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment.
Kulkarni S, Nancy K, Formica R, Moeckel G, Pober J. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment. Transplantation 2014, 98: 79. DOI: 10.1097/00007890-201407151-00247.Peer-Reviewed Original Research
2010
Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature
Cuffy MC, Singh M, Formica R, Simmons E, Abu Alfa AK, Carlson K, Girardi M, Cowper SE, Kulkarni S. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrology Dialysis Transplantation 2010, 26: 1099-1101. PMID: 21079195, DOI: 10.1093/ndt/gfq693.Peer-Reviewed Case Reports and Technical NotesConceptsNephrogenic systemic fibrosisRenal transplantationSystemic fibrosisSymptoms of NSFEarly renal transplantationUnderwent renal transplantationRare fibrosing disorderStandard therapy existsRenal functionFibrosing disorderRenal diseaseCase reportTherapy existsPatient's lesionTherapeutic modalitiesTransplantationPatientsLesionsFibrosisPhotopheresisPlasmapheresisImatinibSymptomsCareful considerationDiseaseAccepting a donor kidney: an evaluation of patients’ and transplant surgeons’ priorities
Solomon DA, Rabidou N, Kulkarni S, Formica R, Fraenkel L. Accepting a donor kidney: an evaluation of patients’ and transplant surgeons’ priorities. Clinical Transplantation 2010, 25: 786-793. PMID: 20964716, PMCID: PMC4846340, DOI: 10.1111/j.1399-0012.2010.01342.x.Peer-Reviewed Original ResearchConceptsKidney qualityDonor kidneysTransplant surgeonsEvaluation of patientsMann-Whitney U testTransplant outcomesPatient characteristicsSpearman correlation coefficientPatient prioritiesWaiting listPatientsAvailable kidneysClinical practiceSurgeon rankingsKidneyU testSurgeonsCategorical variablesPatient autonomyComputer surveyCorrelation coefficientTransplantationFactorsGreat valueOUTCOMES OF DONOR EVALUATIONS FOR LIVING DONOR LIVER TRANSPLANTATION (LDLT); WHO IS THE IDEAL DONOR? IS THERE ROOM FOR IMPROVEMENT?
Arvelakis A, Kulkarni S, Emre S. OUTCOMES OF DONOR EVALUATIONS FOR LIVING DONOR LIVER TRANSPLANTATION (LDLT); WHO IS THE IDEAL DONOR? IS THERE ROOM FOR IMPROVEMENT? Transplantation 2010, 90: 75. DOI: 10.1097/00007890-201007272-00143.Peer-Reviewed Original ResearchKidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information?
Formica RN, Asch WS, Wagner KR, Kulkarni S. Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information? Clinical Journal Of The American Society Of Nephrology 2010, 5: 924-928. PMID: 20203162, PMCID: PMC2863980, DOI: 10.2215/cjn.06820909.Peer-Reviewed Original ResearchConceptsHIV-positive individualsKidney transplantationMedical historyRecipient's medical historyAlternative treatment optionHIV statusKidney donorsTreatment optionsKidney donationConsensus groupTransplantationDonation procedureAbstractTextRecipient's rightRecipientsPotential donorsHealth informationPotential recipientsSpecific diseasesPanel reviewHIVDonors' rightsRiskDonorsState statues
2006
Ethics in Liver Transplantation
Kulkarni S, Cronin D. Ethics in Liver Transplantation. Seminars In Liver Disease 2006, 26: 234-238. PMID: 16850372, DOI: 10.1055/s-2006-947299.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseDeceased donor liversLiver transplantationLiver diseaseManagement of comorbiditiesDeceased donor kidneysGraft survivalPreferred therapyLifesaving therapyCurrent allocation systemSurgical techniqueTransplantationPatientsLiverTherapyDiseaseInadequate supplyDeficiencyComorbiditiesImmunosuppressionMELDKidneyMortalitySuch deficienciesSpectacular improvementLiving donor liver transplantation for pediatric and adult recipients
Kulkarni S, Malagò M, Cronin DC. Living donor liver transplantation for pediatric and adult recipients. Nature Reviews Gastroenterology & Hepatology 2006, 3: 149-157. PMID: 16511549, DOI: 10.1038/ncpgasthep0437.Peer-Reviewed Original Research
2003
The sickest first? Disparities with model for end‐stage liver disease‐based organ allocation: One region's experience
Schaffer RL, Kulkarni S, Harper A, Millis JM, Cronin DC. The sickest first? Disparities with model for end‐stage liver disease‐based organ allocation: One region's experience. Liver Transplantation 2003, 9: 1211-1215. PMID: 14586883, DOI: 10.1053/jlts.2003.50192.Peer-Reviewed Original ResearchConceptsCadaver liversMELD scoreHepatocellular carcinomaOrgan allocationRegion patientsEnd-stage liver diseaseEquitable organ distributionMean MELD scoreMedian MELD scoreHigh MELD scoreLiver transplant programNumber of transplantationsOrgan Sharing regionsLiver recipientsPretransplantation mortalityMELD exceptionsLiver diseaseSingle centerUnited NetworkTransplant programsWaiting listTransplantationEvidence-based systemOrgan procurementTransplantation Network
1999
Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience
Woodle E, Buell J, Siegel C, Kulkarni S, Kopelan A, Grewal H. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. Transplantation Proceedings 1999, 31: 84-85. PMID: 10576053, DOI: 10.1016/s0041-1345(99)00803-9.Peer-Reviewed Original ResearchConceptsCorticosteroid withdrawalRenal transplantationRescue therapyChicago experienceTransplantationTherapyEARLY CORTICOSTEROID WITHDRAWAL WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNO-SUPPRESSION IN RENAL TRANSPLANTATION: EIGHTEEN-MONTH FOLLOW-UP
BUELL J, GREWAL H, KRISTO B, KOPELAN A, KULKARNI S, YOSHIDA A, KIM E, SIEGEL C, CRONIN D, BRUCE D, NEWELL K, MILLIS J, THISTLETHWAITE J, WOODLE E. EARLY CORTICOSTEROID WITHDRAWAL WITH TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IMMUNO-SUPPRESSION IN RENAL TRANSPLANTATION: EIGHTEEN-MONTH FOLLOW-UP. Transplantation 1999, 67: s545. DOI: 10.1097/00007890-199905150-00037.Peer-Reviewed Original Research